Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Rationale: Chronic HCV infection is characterised by a weak HCV specific CD8+ T cell response, due to continuous pressure of high viral load. Treatment of chronic HCV patients with ASV and DCV will result in a significant drop in HCV viral load. At present, no information is available on the immunological effects of treatment with ASV and DCV, nor on the early effects of viral load reduction caused by a compound that is thought not to possess direct immunomodulatory effects. This information will be crucial for a better understanding of the mechanisms that may limit the effectiveness of treatment, occurrence of viral rebound or relapses during, at the end of treatment or during the follow up period.

Objective: To evaluate in detail the functionality of immune cells in blood in chronic HCV patients before, during and after treatment with ASV and DCV, in an IFN-free regimen.

Study design: This is an investigator-initiated single center open label study with one arm of 12 patients.

Study population: Adult chronic HCV patients with genotype 1b, who are previous non-responders to the treatment.

Intervention (if applicable): All patients will be treated with twice daily a 200 mg oASV and once daily a 60 mg DCV for 24 weeks.

Main study parameters/endpoints:

1. Phenotype and function of blood leukocytes during treatment; frequency of HCV-specific T cells, NK cells and monocytes

2. Gene expression levels of leukocyte populations before, during and after treatment

3. Gene expression levels of the type I IFN signaling pathway on whole blood samples

4. Serum cytokines levels using multiplex platforms

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Foundation for Liver Research
• Treatments: Asunaprevir

Criteria

Inclusion Criteria:

• Patients between 18 and 70 years of age, with a chronic hepatitis C - genotype 1b infection

• Patients are non-responders to previous treatment with peginterferon or conventional interferon plus ribavirin combination therapy

• High viral load (>400,000 IU/ml)

• Indication for antiviral therapy of hepatitis C according to current clinical guidelines

• Written informed consent

Exclusion Criteria:

• Decompensated cirrhosis (Child-Pugh Grade B or C)

• Hepatic imaging (ultrasound, CT or MRI) with the evidence of hepatocellular carcinoma within the last 3 months.

• Females who are pregnant or breast-feeding

• History or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigators, unsuitable for the study

• Co-infections with human immunodeficiency virus (HIV) or Hepatitis B virus (HBV)

• Presence of contra-indications for antiviral therapy with ASV and DCV:

• Interfering substance abuse, such as high alcohol intake (indicator: 28 drinks/ week)

• Any exposure to NS3 protease inhibitors or NS5A polymerase inhibitors

• Treatment with peginterferon/ ribavirin within 6 months before start of therapy

• Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating and completing in the study